FDG-PET and Beyond: Molecular Breast Cancer Imaging
- 10 March 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (8) , 1664-1673
- https://doi.org/10.1200/jco.2005.11.024
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- PET with [ 18 F]fluorothymidine for imaging of primary breast cancer: a pilot studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study GroupJournal of Clinical Oncology, 2004
- Determinants of Diagnostic Performance Of [F-18]Fluorodeoxyglucose Positron Emission Tomography for Axillary Staging in Breast CancerAnnals of Surgery, 2002
- Molecular imaging of cancer with positron emission tomographyNature Reviews Cancer, 2002
- Comparing whole body 18 F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Positron Emission Tomography and Sentinel Lymph Node Dissection in Breast CancerClinical Breast Cancer, 2002
- Detection of Occult Disease in Breast Cancer Using Fluorodeoxyglucose Camera-Based Positron Emission TomographyClinical Breast Cancer, 2001
- The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast CancerClinical Positron Imaging, 2000
- Staging of the Axilla in Breast CancerAnnals of Surgery, 1998
- Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogensEuropean Journal of Cancer and Clinical Oncology, 1983